Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PRMT5 | O14744 | 1/20 | 0.66 |
| ▸ | WDR77 | Q9BQA1 | 1/20 | 0.66 |
| ▸ | AHCY | P23526 | 11/20 | 0.65 |
| ▸ | NADK | O95544 | 1/20 | 0.65 |
| ▸ | ADORA2A | P29274 | 2/20 | 0.65 |
| ▸ | ADORA2B | P29275 | 2/20 | 0.65 |
| ▸ | DPP4 | P27487 | 1/20 | 0.65 |
| ▸ | MEN1 | O00255 | 1/20 | 0.65 |
| ▸ | SLC28A1 | O00337 | 1/20 | 0.65 |
| ▸ | MAP3K7 | O43318 | 1/20 | 0.65 |
| ▸ | SLC28A2 | O43868 | 1/20 | 0.65 |
| ▸ | GAPDH | P04406 | 1/20 | 0.65 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.65 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.65 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.65 |
| ▸ | STAT6 | P42226 | 1/20 | 0.65 |
| ▸ | PI4KA | P42356 | 1/20 | 0.65 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.65 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.65 |
| ▸ | PI4K2B | Q8TCG2 | 1/20 | 0.65 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31680251 | 0.92 | AHCY (0.68) | PRMT5WDR77AHCYADORA2AADORA2B | |
| SCHEMBL397800 | 0.92 | AHCY (0.68) | PRMT5WDR77AHCYADORA2AADORA2B | |
| SCHEMBL7803295 | 0.91 | AHCY (0.67) | PRMT5WDR77AHCYADORA2AADORA2B | |
| SCHEMBL6671788 | 0.91 | AHCY (0.67) | PRMT5WDR77AHCYADORA2AADORA2B | |
| SCHEMBL3478038 | 0.89 | AHCY (0.65) | PRMT5WDR77AHCYADORA2AADORA2B | |
| SCHEMBL22326787 | 0.89 | PRMT5 (0.64) | PRMT5WDR77AHCYADORA2AADORA2B | |
| SCHEMBL13173634 | 0.89 | PRMT5 (0.64) | PRMT5WDR77AHCYADORA2AADORA2B | |
| SCHEMBL21413837 | 0.89 | PRMT5 (0.64) | PRMT5WDR77AHCYADORA2AADORA2B | |
| SCHEMBL22326785 | 0.89 | PRMT5 (0.64) | PRMT5WDR77AHCYADORA2AADORA2B | |
| SCHEMBL10997934 | 0.89 | AHCY (0.65) | PRMT5WDR77AHCYADORA2AADORA2B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230324392-A1 | METHODS AND COMPOSITIONS FOR TARGETING CYTOSOLIC DSDNA SIGNALING IN CHROMOSOMALLY UNSTABLE CANCERS | MEMORIAL SLOAN KETTERING CANCER CENTER (US) | 2023-10-12 | — | — | US | claimed |
| US-20130023491-A1 | BETA-CELL REPLICATION PROMOTING COMPOUNDS AND METHODS OF THEIR USE | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2013-01-24 | — | — | US | claimed |
| EP-2513298-A2 | BETA-CELL REPLICATION PROMOTING COMPOUNDS AND METHODS OF THEIR USE | President and Fellows of Harvard College (US) | 2012-10-24 | — | — | EP | claimed |
| WO-2011075665-A2 | BETA-CELL REPLICATION PROMOTING COMPOUNDS AND METHODS OF THEIR USE | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2011-06-23 | — | — | WO | claimed |
| CN-119709746-A | Extrahepatic delivery | 阿尔尼拉姆医药品有限公司 | 2025-03-28 | — | — | CN | disclosed |
| CN-114945669-B | Extrahepatic delivery | 阿尔尼拉姆医药品有限公司 | 2025-01-10 | — | — | CN | disclosed |
| US-20230324392-A1 | METHODS AND COMPOSITIONS FOR TARGETING CYTOSOLIC DSDNA SIGNALING IN CHROMOSOMALLY UNSTABLE CANCERS | MEMORIAL SLOAN KETTERING CANCER CENTER (US) | 2023-10-12 | — | — | US | disclosed |
| US-20230304002-A1 | TRANSTHYRETIN (TTR) iRNA COMPOSITIONS AND METHODS OF USE THEREOF FOR TREATING OR PREVENTING TTR-ASSOCIATED OCULAR DISEASES | BANK OF AMERICA, N.A. | 2023-09-28 | — | — | US | disclosed |
| US-20230272382-A1 | COMPLEMENT COMPONENT C3 iRNA COMPOSITIONS AND METHODS OF USE THEREOF FOR TREATING OR PREVENTING COMPLEMENT COMPONENT C3-ASSOCIATED DISEASES | BANK OF AMERICA, N.A. | 2023-08-31 | — | — | US | disclosed |
| EP-4208572-A1 | METHODS AND COMPOSITIONS FOR TARGETING CYTOSOLIC DSDNA SIGNALING IN CHROMOSOMALLY UNSTABLE CANCERS | Memorial Sloan Kettering Cancer Center (US) | 2023-07-12 | — | — | EP | disclosed |
| US-20230016929-A1 | EXTRAHEPATIC DELIVERY | BANK OF AMERICA, N.A. | 2023-01-19 | — | — | US | disclosed |
| EP-4055166-A2 | EXTRAHEPATIC DELIVERY | Alnylam Pharmaceuticals, Inc. (US) | 2022-09-14 | — | — | EP | disclosed |
| EP-2513298-A2 | BETA-CELL REPLICATION PROMOTING COMPOUNDS AND METHODS OF THEIR USE | President and Fellows of Harvard College (US) | 2012-10-24 | — | — | EP | disclosed |
| WO-2011075665-A2 | BETA-CELL REPLICATION PROMOTING COMPOUNDS AND METHODS OF THEIR USE | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2011-06-23 | — | — | WO | disclosed |
| US-7465544-B2 | Synthetic cofactor analogs of S-adenosylmethionine as ligatable probes of biological methylation and methods for their use | WISCONSIN ALUMNI RESEARCH FOUNDATION (US) | 2008-12-16 | — | — | US | disclosed |
| EP-1578931-A4 | METHODS OF IDENTIFYING COMPOUNDS THAT MODULATE IL-4 RECEPTOR-MEDIATED IGE SYNTHESIS UTILIZING AN ADENOSINE KINASE | RIGEL PHARMACEUTICALS INC (US) | 2007-09-12 | — | — | EP | disclosed |
| US-20070161007-A1 | Synthetic cofactor analogs of S-adenosylmethionine as ligatable probes of biological methylation and methods for their use | WISCONSIN ALUMNI RESEARCH FOUNDATION (US) | 2007-07-12 | — | — | US | disclosed |
| US-20060166201-A1 | Method for the detection of nucleic acid sequences by means of crackable probe molecules | EPIGENOMICS AG (DE) | 2006-07-27 | — | — | US | disclosed |
| EP-1578931-A2 | METHODS OF IDENTIFYING COMPOUNDS THAT MODULATE IL-4 RECEPTOR-MEDIATED IGE SYNTHESIS UTILIZING AN ADENOSINE KINASE | Rigel Pharmaceuticals, Inc. (US) | 2005-09-28 | — | — | EP | disclosed |
| WO-2004007680-A2 | METHODS OF IDENTIFYING COMPOUNDS THAT MODULATE IL-4 RECEPTOR-MEDIATED IGE SYNTHESIS UTILIZING AN ADENOSINE KINASE | RIGEL PHARMACEUTICALS, INC. (US) | 2004-01-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130023491-A1 | BETA-CELL REPLICATION PROMOTING COMPOUNDS AND METHODS OF THEIR USE | ADK, AHCY, IAPP | PRMT5 311/4885WDR77 460/4885AHCY 2/4885 |
| US-20230304002-A1 | TRANSTHYRETIN (TTR) iRNA COMPOSITIONS AND METHODS OF USE THEREOF FOR TREATING OR PREVENTING TTR-ASSOCIATED OCULAR DISEASES | TTR, MTPN, CRYAA | PRMT5 4030/4885WDR77 3518/4885AHCY 1210/4885 |
| US-20230016929-A1 | EXTRAHEPATIC DELIVERY | SLC10A1, FABP1, SLC67A1 | PRMT5 3893/4885WDR77 1304/4885AHCY 2195/4885 |
| US-20070161007-A1 | Synthetic cofactor analogs of S-adenosylmethionine as ligatable probes of biological methylation and methods for their use | DNMT1, MAT2A, MAT1A | PRMT5 23/4885WDR77 832/4885AHCY 6/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.